How it works
Represents the lipolytic C-terminal region of hGH. In adipocytes it stimulates lipolysis and inhibits lipogenesis without binding the GH receptor, so IGF-1 and glucose remain unaffected.
Structure: Fragment 176-191 of human growth hormone
Reported benefits
- Fat mobilisation without IGF-1 elevation
- No reported impact on insulin sensitivity
- Good tolerability profile in trials
Practical considerations
- Phase IIb trials failed to beat placebo for weight loss at 12 weeks
- Popular in clinics despite weak efficacy data
- Best viewed as adjunctive, not a primary fat-loss tool
Side effects and risks
- Generally well tolerated
- Occasional injection-site reaction
- Headache
Dosing overview
Commonly cited at 300 mcg daily, 5 days on / 2 off
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
Research references
- Heffernan et al., 2001 — AOD-9604 and adipose tissue metabolism